Burosumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | FGF 23 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1610833-03-8 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6388H9904N1700O2006S46 |
| Molar mass | 144.1 kDa |
Burosumab (INN) is a human monoclonal antibody designed for the treatment of X-linked hypophosphatemia.[1][2]
This drug was developed by Ultragenyx.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Burosumab, American Medical Association.
- ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.